
    
      OUTLINE:

      Patients receive anakinra subcutaneously (SC) daily on days 0-13 and axicabtagene ciloleucel
      via infusion on day 0.

      After completion of axicabtagene ciloleucel infusion, patients are followed up periodically
      for up to 90 days.
    
  